Sanofi unveils heart disease partnership with MyoKardia

September 17
3:23 AM 2014

French drugmaker Sanofi announced on Wednesday a partnership with U.S.-based MyoKardia to develop therapies for patients with genetic heart diseases.

The collaboration includes up to $200 million in equity investments, milestone payments, and research and development services through 2018, Sanofi said in a statement.

MyoKardia was founded in 2012 and is funded by healthcare investor Third Rock Ventures.

© 2022 VCPOST, All rights reserved. Do not reproduce without permission.


Join the Conversation

Subscribe to VCpost newsletter

Sign up for our Deals of the Day newsletter.
We will not spam you!

Real Time Analytics